Literature DB >> 17188914

Protein 4.2 Komatsu (D175Y) associated with the lack of interaction with ankyrin in human red blood cells.

Yang Su1, Yu Ding, Ming Jiang, Xiaojian Hu, Zhihong Zhang.   

Abstract

Membrane skeletal proteins play an important role in regulating the shape and function of the human red blood cell. Protein 4.2 interacts with cytoplasmic domain of band 3 (CDB3) and ankyrin for association between the skeleton network and the membrane. The deficiency of protein 4.2 may result in hereditary spherocytosis. In order to explore the molecular mechanism of the linkage of protein 4.2 Komatsu (D175Y) and protein 4.2 Nippon (A142T) with hereditary spherocytosis, a series of protein 4.2-derived mutants were designed and expressed in Escherichia coli. Their interactions with ankyrin and CDB3 were investigated by Far Western blot and pull-down assay in vitro. The results showed that the mutant D175Y of protein 4.2 cannot interact with ankyrin while mutant A142T, just like normal protein 4.2, can bind to ankyrin directly and can associate with CDB3 in the presence of ankyrin. Based on comparing the binding abilities of the protein 4.2 mutants D175F, D175A, D175K and D175Y with ankyrin and CDB3, we suggested that defective binding of protein 4.2 Komatsu to ankyrin is resulted from the charge effect of amino acid residue 175 substitution (D-->Y), which leads to significant structural change in protein 4.2 function domain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188914     DOI: 10.1016/j.bcmd.2006.11.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  1 in total

1.  Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2).

Authors:  Emile van den Akker; Timothy J Satchwell; Stephanie Pellegrin; Joanna F Flatt; Michel Maigre; Geoff Daniels; Jean Delaunay; Lesley J Bruce; Ashley M Toye
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.